文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

阿奇霉素调控ANXA1抑制Notch1/NF-κB通路抑制M1巨噬细胞极化减轻LPS诱导的急性肾损伤

AZITHROMYCIN REGULATES ANXA1-SUPPRESSED NOTCH1/NF-ΚB PATHWAY TO INHIBIT M1 MACROPHAGE POLARIZATION AND ATTENUATES LPS-INDUCED AKI.
PubMed 文献 · Shock · 2025-06-06
一句话结论小鼠与体外实验显示阿奇霉素经上调ANXA1、抑制Notch1/NF-κB通路减少M1巨噬细胞极化,减轻LPS诱导的急性肾损伤。

该研究在7周龄C57BL/6小鼠构建LPS诱导的急性肾损伤模型,并在体外观察阿奇霉素对巨噬细胞极化的作用。阿奇霉素降低了LPS诱导AKI小鼠的血肌酐、血尿素氮、肾小管损伤评分和NGAL阳性表达率,抑制IL-6、IL-1β、TNF-α、iNOS和CD86水平,促进IL-10和精氨酸酶-1水平。体外实验显示阿奇霉素抑制LPS诱导的M1巨噬细胞极化。机制上阿奇霉素促进ANXA1表达、抑制notch受体1和核因子κB亚基1表达,并通过上调ANXA1减轻炎症与M1极化。作者认为这些发现可能加速LPS相关AKI临床药物的转化。

要点

  • 在LPS诱导AKI小鼠中,阿奇霉素降低血肌酐、血尿素氮、肾小管损伤评分和NGAL阳性表达率。
  • 阿奇霉素降低LPS诱导AKI组IL-6、IL-1β、TNF-α、iNOS和CD86水平,升高IL-10和精氨酸酶-1水平。
  • 体外实验中阿奇霉素抑制LPS诱导的M1巨噬细胞极化。
  • 体内外阿奇霉素均促进ANXA1表达、抑制notch受体1和核因子κB亚基1表达,并通过上调ANXA1减轻炎症和M1极化。
  • 作者认为这些发现可能加速LPS相关AKI临床药物的转化。

适用人群与场景

  • 7周龄C57BL/6小鼠构建的LPS诱导急性肾损伤模型,以及体外LPS诱导的巨噬细胞极化模型。

研究设计与关键结果

  • 研究类型为动物实验与体外细胞实验;在LPS诱导AKI小鼠中,阿奇霉素降低血肌酐、血尿素氮、肾小管损伤评分和NGAL阳性表达率。
  • 阿奇霉素抑制LPS诱导AKI组的IL-6、IL-1β、TNF-α、iNOS和CD86水平,促进IL-10和精氨酸酶-1水平。
  • 体外实验显示阿奇霉素抑制LPS诱导的M1巨噬细胞极化。
  • 体内和体外阿奇霉素均促进ANXA1表达、抑制notch受体1和核因子κB亚基1表达;阿奇霉素通过上调ANXA1减轻炎症和M1巨噬细胞极化。

证据类型、等级与局限

  • 证据类型:动物实验与体外细胞实验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文未据此给出临床推荐;作者认为这些发现可能加速LPS相关AKI临床药物的转化。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Background: Acute kidney injury (AKI) is a common and severe form of renal dysfunction, characterized by inflammation and damage to tubular epithelial cells. Azithromycin (AZM) possesses anti-inflammatory and immunomodulatory properties. In this study, we aim to elucidate the underlying functional roles of AZM in lipopolysaccharide (LPS)-induced AKI. Methods: C57BL/6 mice (7 weeks old) were used to construct the AKI models in vivo . The serum creatinine (Scr) level, blood urea nitrogen (BUN) levels, tubular damage score, and NGAL-positive expression were examined using Scr and BUN assay kits, hematoxylin and eosin staining, and immunohistochemistry, respectively. The reverse transcription-quantitative polymerase chain reaction (qRT-PCR) and western blot were performed to detect the levels of target genes. The cell viability was examined using cell counting kit-8 (CCK8). The interleukin (IL)-6, IL-1β, tumor necrosis factor-alpha (TNF-α), and IL-10 levels were analyzed using corresponding enzyme-linked immunosorbent (ELISA) detection kits. The macrophage polarization was detected using western blot and flow cytometry. Results: AZM reduced Scr level, BUN levels, tubular damage score, and NGAL-positive expression rate in LPS-induced AKI model in vivo . AZM repressed IL-6, IL-1β, TNF-α, inducible nitric oxide synthase (iNOS), and CD86 levels and promoted IL-10 and Arginase-1 levels in LPS-induced AKI group. Additionally, AZM suppressed LPS-induced M1 macrophage polarization in vitro . AZM expedited ANXA1 expression and inhibited notch receptor 1 and nuclear factor kappa B subunit 1 expression in vivo and in vitro . Furthermore, AZM alleviated inflammation and M1 macrophage polarization through ANXA1 upregulation. Conclusion: AZM remits LPS-induced AKI by regulating M1 macrophage polarization via regulating ANXA1 and notch receptor 1/nuclear factor kappa B subunit 1 pathway. These findings may accelerate the translation of clinical drugs for the treatment of LPS-associated AKI.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Li Q, Lei Y, Zhou R, et al. AZITHROMYCIN REGULATES ANXA1-SUPPRESSED NOTCH1/NF-ΚB PATHWAY TO INHIBIT M1 MACROPHAGE POLARIZATION AND ATTENUATES LPS-INDUCED AKI. Shock. 2025. PMID: 40663483. doi:10.1097/SHK.0000000000002641

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。